ReviewFrontiers in cellular and infection microbiology2026
The single-cell immune atlas of bacterial pneumonia: from inflammatory cell infiltration to treatable cell states.
Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial pneumonia remains a major cause of infectious mortality, and antimicrobial resistance has intensified interest in host-directed therapy (HDT). Recent bronchoalveolar lavage fluid (BALF) and peripheral blood atlases (2024-2025) provide single-cell evidence from human disease, but the main translational gap is prioritization rather than catalog expansion. In this review, we reorganize published datasets from bacterial pneumonia and related lung infection cohorts (>500,000 cells; 2020-2026) into a state-prioritization scheme termed "treatable cell states." Evidence is currently strongest for severity-linked expansion of indoleamine 2,3-dioxygenase 1-positive/programmed death-ligand 1-positive (IDO1+/PD-L1+) macrophages and pathological neutrophils; exhausted-like CD8+ T-cell states show emerging human transcriptomic and translational support but still require protein-level, functional, and longitudinal validation, whereas evidence for injured epithelium and repair-failed stromal states in bacterial pneumonia remains partly inferential and draws on adjacent lung-injury literature. We therefore treat the six proposed state categories as a ranked hypothesis set for macrophage-, neutrophil-, T-cell-, epithelial-, and stromal-directed interventions, not as validated clinical targets. Most proposed interventions still require longitudinal and functional validation before routine bedside use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.